Asian Pacific Journal of Cancer Prevention

Asian Pacific Journal of Cancer Prevention (아시아태평양암예방학회)
권호 표지
DOI QR코드

DOI QR Code

Serum Kynurenic Acid: Possible Association with Invasiveness of Non-small Cell Lung Cancer

  • Sagan, Dariusz (Department of Thoracic Surgery, Medical University of Lublin) ;
  • Kocki, Tomasz (Department of Experimental and Clinical Pharmacology, Medical University of Lublin) ;
  • Kocki, Janusz (Department of Clinical Genetics, Medical University of Lublin) ;
  • Szumilo, Justyna (Department of Clinical Pathomorphology, Medical University of Lublin)
  • Published : 2012.09.30
Download PDF
⟨ Previous Next ⟩

Abstract

The lung adenocarcinoma is considered more aggressive than other types of non-small cell lung cancer. As metabolites of tryptophan degradation along the kynurenine pathway, including kynurenic acid, have been shown to induce immunosuppression and facilitate escape of tumor cells from immune surveillance, a hypothesis was set up that differences in biological behavior between types of lung cancer may be associated with altered activity of the kynurenine metabolic pathway. The aim of the study was to determine kynurenic acid levels in the serum of patients with bronchial adenocarcinoma for comparison with other types of non-small cell lung cancer. A total of 227 patients with non-small cell lung cancer were enrolled in the study, including 71 with adenocarcinoma and 96 with squamous cell carcinoma. Serum kynurenic acid concentration was determined with use of high performance liquid chromatography and fluorometry. The level of kynurenic acid in the serum of patients with adenocarcinoma was significantly higher than in those with squamous cell lung cancer ($107.1{\pm}62.8$ pmol/ml; 95%CI: 92.4 to 132.3 pmol/ml versus $82.1{\pm}47.6$ pmol/ml; 95%CI: 78.5 to 91.2 pmol/ml, respectively; p = 0.027). Differences between other histological types of lung cancer were insignificant. We conclude that increased activity of kynurenine metabolic pathway manifested by elevated serum kynurenic acid level may be one of the factors associated with clinically distinct biological behavior of adenocarcinoma, in particular high invasiveness and rapid progression.

Keywords

References

  1. Cooke DT, Nguyen DV, Yang Y, et al (2010). Survival comparison of adenosquamous, squamous cell, and adenocarcinoma of the lung after lobectomy. Ann Thorac Surg, 90, 943-8. https://doi.org/10.1016/j.athoracsur.2010.05.025
  2. Dai F, Liu L, Che G, et al (2010). The number and microlocalization of tumor-associated immune cells are associated with patient's survival time in non-small cell lung cancer. BMC Cancer, 10, 220. https://doi.org/10.1186/1471-2407-10-220
  3. Detterbeck FC, Boffa DJ, Tanoue LT (2009). The new lung cancer staging system. Chest,136, 260-71. https://doi.org/10.1378/chest.08-0978
  4. DiNatale BC, Murray IA, Schroeder JC, et al (2010). Kynurenic acid is a potent endogenous aryl hydrocarbon receptor ligand that synergistically induces interleukin-6 in the presence of inflammatory signaling. Toxicol Sci, 115, 89-97. https://doi.org/10.1093/toxsci/kfq024
  5. Foster AC (1986). Involvement of excitatory amino acid receptors in the mechanisms underlying excitotoxic phenomena. Adv Exp Med Biol, 203, 303-16. https://doi.org/10.1007/978-1-4684-7971-3_23
  6. Fulop F, Szatmari I, Vamos E, et al (2009). Syntheses, transformations and pharmaceutical applications of kynurenic acid derivatives. Curr Med Chem, 16, 4828-42. https://doi.org/10.2174/092986709789909602
  7. Hoshi M, Ito H, Fujigaki H, et al (2009). Changes in serum tryptophan catabolism as an indicator of disease activity in adult T-cell leukemia/lymphoma. Leuk Lymphoma, 50, 1372-4. https://doi.org/10.1080/10428190903045393
  8. Huang A, Fuchs D, Widner B, et al (2002). Serum tryptophan decrease correlates with immune activation and impaired quality of life in colorectal cancer. Br J Cancer, 86, 1691-6. https://doi.org/10.1038/sj.bjc.6600336
  9. Karanikas V, Zamanakou M, Kerenidi T, et al (2007). Indoleamine 2,3-dioxygenase (IDO) expression in lung cancer. Cancer Biol Ther, 6, 1258-62. https://doi.org/10.4161/cbt.6.8.4444
  10. Lob S, Konigsrainer A, Zieker D, et al (2009). IDO1 and IDO2 are expressed in human tumors: levo- but not dextro-1- methyl tryptophan inhibits tryptophan catabolism. Cancer Immunol Immunother, 58, 153-7. https://doi.org/10.1007/s00262-008-0513-6
  11. Maeda R, Yoshida J, Ishii G, et al (2011). Risk factors for tumor recurrence in patients with early-stage (stage I and II) non-small cell lung cancer: Patient selection criteria for adjuvant chemotherapy according to the 7th edition TNM classification. Chest, doi: 10.1378/chest.10-3279.
  12. Mellor AL, Keskin DB, Johnson T, et al (2002). Cells expressing indoleamine 2,3-dioxygenase inhibit T cell responses. J Immunol, 168, 3771-6. https://doi.org/10.4049/jimmunol.168.8.3771
  13. Munn DH, Mellor AL (2007). Indoleamine 2,3-dioxygenase and tumor-induced tolerance. J Clin Invest, 117, 1147-54. https://doi.org/10.1172/JCI31178
  14. Munn DH, Shafizadeh E, Attwood JT, et al (1999). Inhibition of T cell proliferation by macrophage tryptophan catabolism. J Exp Med, 189, 1363-72. https://doi.org/10.1084/jem.189.9.1363
  15. Schroecksnadel K, Winkler C, Fuith LC, Fuchs D (2005). Tryptophan degradation in patients with gynecological cancer correlates with immune activation. Cancer Lett, 223, 323-9. https://doi.org/10.1016/j.canlet.2004.10.033
  16. Suzuki Y, Suda T, Furuhashi K, et al (2010). Increased serum kynurenine/tryptophan ratio correlates with disease progression in lung cancer. Lung Cancer, 67, 361-5. https://doi.org/10.1016/j.lungcan.2009.05.001
  17. Tomaszek SC, Kim Y, Cassivi SD, et al (2011). Bronchial resection margin length and clinical outcome in non-small cell lung cancer. Eur J Cardiothorac Surg, doi:10.1016/j.ejcts.2011.02.042.
  18. Travis WD, Brambilla E, Muller-Hermelink HK, Harris CC (2004). Pathology and genetics of tumors of the lung, pleura, thymus and heart. WHO Classification of Tumors. 1st. ed. Lyon. IARC Press.
  19. Walczak K, Browski D, Langner E, et al (2011). Kynurenic acid synthesis and kynurenine aminotransferases expression in colon derived normal and cancer cells. Scand J Gastroenterol, 46, 903-12. https://doi.org/10.3109/00365521.2011.579159
  20. Wang J, Simonavicius N, Wu X, et al (2006). Kynurenic acid as a ligand for orphan G protein-coupled receptor GPR35. J Biol Chem, 281, 22021-8. https://doi.org/10.1074/jbc.M603503200
  21. Watanabe K, Emoto N, Hamano E, et al (2011). Genome structure-based screening identified epigenetically silenced microRNA associated with invasiveness in non-small-cell lung cancer. Int J Cancer, doi: 10.1002/ijc.26254.
  22. Witkiewicz A, Williams TK, Cozzitorto J, et al (2008). Expression of indoleamine 2,3-dioxygenase in metastatic pancreatic ductal adenocarcinoma recruits regulatory T cells to avoid immune detection. J Am Coll Surg, 206, 849-854. https://doi.org/10.1016/j.jamcollsurg.2007.12.014
  23. Zdzisinska B, Wejksza K, Walter-Croneck A, et al (2010). Kynurenic acid in blood and bone marrow plasma of monoclonal gammopathy of undetermined significance (MGUS) and multiple myeloma (MM) patients. Leuk Res, 34, 38-45. https://doi.org/10.1016/j.leukres.2009.06.015

Cited by

  1. Induction of Indoleamine 2,3-dioxygenase (IDO) Enzymatic Activity Contributes to Interferon-Gamma Induced Apoptosis and Death Receptor 5 Expression in Human Non-small Cell Lung Cancer Cells vol.15, pp.18, 2014, https://doi.org/10.7314/APJCP.2014.15.18.7995
  2. Quinolinic acid induces neuritogenesis in SH-SY5Y neuroblastoma cells independently of NMDA receptor activation vol.45, pp.5, 2017, https://doi.org/10.1111/ejn.13499